Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.36 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815645 | 0.89 | GGPS1 (0.40) | GGPS1TOP2ASLC9A1PTGS2HSD11B1 | |
| SCHEMBL945084 | 0.85 | GGPS1 (0.43) | GGPS1SLC9A1PTGS2HCAR3 | |
| SCHEMBL14981007 | 0.83 | TOP2A (0.38) | GGPS1TOP2ASLC9A1POLBPTGS2 | |
| SCHEMBL18163273 | 0.82 | GGPS1 (0.40) | GGPS1TOP2ASLC9A1POLBPTGS2 | |
| SCHEMBL16815524 | 0.79 | MGMT (0.38) | GGPS1PTGS2HSD11B1MGMTHCAR3 | |
| SCHEMBL3546972 | 0.78 | GGPS1 (0.51) | GGPS1TOP2ASLC9A1HSD11B1MGMT | |
| Hydrochloric Acid SCHEMBL5655674 | 0.78 | MGMT (0.47) | GGPS1TOP2ASLC9A1POLBPTGS2 | |
| SCHEMBL16815508 | 0.77 | ALOX5 (0.35) | GGPS1PTGS2MGMTALDH1A1 | |
| SCHEMBL3540867 | 0.76 | GGPS1 (0.53) | GGPS1SLC9A1 | |
| SCHEMBL5020876 | 0.76 | GGPS1 (0.53) | GGPS1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | GGPS1 2444/4885TOP2A 1953/4885SLC9A1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.